Theravance Biopharma Q2 net income $54.8M driven by $225M TRELEGY royalty sale; YUPELRI sales +22%

Theravance Biopharma, Inc.

2025-Q2 EPS reported $0.81 revenue$41,583,000

YUPELRI net sales $66.3M (Viatris-recorded) up 22% YoY; Q2 implied 35% share $23.2M.
Completed sale of TRELEGY royalty interest to GSK for $225M; net gain of $75.1M.
Pivotal Phase 3 CYPRESS study enrollment nearing completion; top-line data ~6 months later.
Cash $339M, no debt; TRELEGY YTD sales on track for $50M milestone in 2025.
Non-GAAP net loss from operations improved to $4.2M from $6.3M YoY.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.